Valuation: Natera, Inc.

Market Cap 59.22B 53.13B 49.12B 44.49B 83.11B 5,640B 84.12B 587B 234B 2,951B 222B 218B 9,369B P/E 2026 *
-286x
P/E 2027 * -3,662x
Enterprise Value 58.13B 52.15B 48.22B 43.67B 81.59B 5,536B 82.57B 577B 230B 2,897B 218B 214B 9,197B EV / Sales 2026 *
20x
EV / Sales 2027 * 16.4x
Free-Float
97.24%
Yield 2026 *
-
Yield 2027 * -
1 day+4.48%
1 week+3.36%
Current month+3.37%
1 month+3.76%
3 months+69.40%
6 months+113.44%
Current year+86.50%
1 week 383.76
Extreme 383.76
432.84
1 month 380.39
Extreme 380.39
437.41
Current year 181
Extreme 181
437.41
1 year 181
Extreme 181
437.41
3 years 36.9
Extreme 36.9
437.41
5 years 26.1
Extreme 26.1
437.41
10 years 7.35
Extreme 7.35
437.41
Manager TitleAgeSince
Chief Executive Officer 47 01/01/2019
President 46 31/08/2023
Director of Finance/CFO 45 31/01/2017
Director TitleAgeSince
Chairman 53 30/04/2015
Director/Board Member 53 31/12/2006
Director/Board Member 47 01/01/2019
Date Insider Type Main position Quantity % Market Cap. Importance
15/10/26 Exercice

Founder

150,000 0.1041%
07/10/26 Don

Founder

-6,000 0.0042%
01/10/26 Sell

Chief Executive Officer

-1,273 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
+4.25%+3.36%+125.38%+1,037.82% 59.22B
-0.86%-3.26%+9.98%+32.92% 117B
+3.04%+0.55%-0.97%+106.83% 97.42B
-0.18%+3.23%-5.94%+90.00% 29.03B
+9.74%+12.87%+40.71%+84.40% 26.86B
+1.57%+2.87%+37.86%+89.92% 26.69B
+2.94%+0.11%+31.67%+405.97% 21.1B
+0.95%+2.20%-16.82%-0.93% 20.61B
-0.13%-1.01%-6.23%+31.16% 16.94B
-3.23%-23.13%-21.13%+54.34% 14.16B
Average +1.87%-2.26%+19.45%+193.24% 42.86B
Weighted average by Cap. +1.88%-1.99%+24.13%+216.59%

Financials

2026 *2027 *
Net sales 2.91B 2.61B 2.41B 2.19B 4.08B 277B 4.13B 28.86B 11.5B 145B 10.92B 10.69B 460B 3.52B 3.16B 2.92B 2.64B 4.94B 335B 5B 34.89B 13.9B 175B 13.2B 12.92B 557B
Net income -203M -182M -169M -153M -285M -19.36B -289M -2.02B -803M -10.13B -763M -747M -32.16B -8.5M -7.63M -7.05M -6.39M -11.93M -810M -12.08M -84.32M -33.58M -424M -31.9M -31.23M -1.35B
Net Debt -1.09B -977M -903M -818M -1.53B -104B -1.55B -10.8B -4.3B -54.25B -4.08B -4B -172B -1.4B -1.26B -1.16B -1.05B -1.97B -134B -1.99B -13.92B -5.55B -69.97B -5.27B -5.16B -222B
Projected Income Statement - Annual - Natera, Inc.
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
28/10/26 US$429.49 +4.54% 856,499
27/10/26 US$410.82 +1.46% 1,713,547
26/10/26 US$404.90 +0.24% 1,429,671
23/10/26 US$403.95 +0.64% 1,102,134
22/10/26 US$401.37 -2.91% 1,611,868
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
MarketScreener Ratings - Natera, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
410.82USD
Average target price
411.39USD
Spread / Average Target
+0.14%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Natera, Inc.
  1. Stock Market
  2. Stocks
  3. NTRA Stock